This review found that addition of bevacizumab improved progression-free overall survival in patients with advanced colorectal cancer who received first-or second-line fluoropyrimidine-based chemotherapy, but at the expense of increased incidence of toxicity. These conclusions were supported by the data, but should be interpreted with some caution due to the possibility of missing studies and the heterogeneity between studies.
Authors' objectives
To determine whether the evidence supports the addition of bevacizumab to cytotoxic chemotherapy for patients with locally advanced non-resectable or metastatic colorectal cancer who are considered suitable candidates for systemic therapy.
Searching
MEDLINE, EMBASE and The Cochrane Library were searched from 1996 to April 2008 for studies published in English. Search terms were reported. Relevant conference proceedings were screened. Abstracts were eligible, but those that reported only preliminary or interim data were excluded.
Study selection
Randomised controlled trials (RCTs) that compared chemotherapy plus bevacizumab with chemotherapy alone in the treatment of adult patients with advanced colorectal cancer were eligible for inclusion. Studies had to report data on overall survival, progression-free survival and/or objective response rate.
Treatment regimens assessed in the included studies consisted of IFL (bolus 5-fluorouracil/folinic acid/irinotecan), FOLFOX4 (infusion 5-fluorouracil/bolus folinic acid/oxaliplatin), XELOX (capecitabine/oxaliplatin) and 5-FU/FA (5-fluorouracil/folinic acid) alone (or with placebo) compared to the same drugs combined with bevacizumab. The exact dose and schedule varied between studies. Median follow-up (where reported) was 28 months.
Two reviewers independently assessed studies for inclusion. Disagreements were resolved by consensus.
Assessment of study quality
Study quality was assessed based on criteria of funding source, randomisation method, concealment of treatment allocation, blinding, baseline characteristics, follow-up and type of analysis.
The authors did not state how many reviewers performed the quality assessment.
Data extraction
Hazard ratios (HRs) were extracted directly from the included studies for time-to-event outcomes. Variances of hazard ratios were estimated from confidence intervals or log-rank p-values. Dichotomous data were extracted as number of responses, which were used to calculated risk ratios (RRs).
